AstraZeneca’s latest Fasenra campaign harnesses the wind, literally, as the quiet sound of air moving reps healthy breathing.
In TV commercials, music can trigger an emotion, establish a jingle or simply act as a background sound layer.
In pharma ads, subtle background music is particularly common because by FDA rules music can’t be too loud or distracting, especially during risk and benefit readings. The FDA slapped both Sanofi and Celgene with untitled letters for distracting audio playing during risk readings for Toujeo and Otezla TV ads, respectively, in late 2016.
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it’s free.
While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.
Viatris employees rang the Nasdaq bell on Nov. 16, marking the one-year anniversary of the merged Mylan and Pfizer Upjohn company
When Mylan and Pfizer’s Upjohn unit merged last year, headlines touted the $12 billion deal and newly named Viatris as the largest generic drugmaker in the world. But that’s not exactly how the company wanted to be known.
So Viatris — which rhymes with Beatrice — began working to create a new brand and culture from scratch around its distinct mix of old pharma blockbusters while layering in a massive portfolio of generic and OTC meds and building up a fresh pipeline of biosimilars.
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it’s free.
GlaxoSmithKline has appointed Philip Dormitzer, formerly chief scientific officer of Pfizer’s viral vaccines unit, as its newest global head of vaccines R&D, looking to leverage one of the leading minds behind Pfizer and BioNTech’s RNA collaboration that led to Covid-19 jab Comirnaty, the British drug giant said Tuesday.
Dormitzer had been with Pfizer for a little more than six years, joining up after a seven-year stint with Novartis, where he reached the role of US head of research and head of global virology for the company’s vaccines and diagnostics unit.
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it’s free.
Tillman Gerngross (Adagio)
Tillman Gerngross, the rarely shy Dartmouth professor, biotech entrepreneur and antibody expert, has been warning for over a year that the virus behind Covid-19 would likely continue to mutate, potentially in ways that avoid immunity from infection and the best defenses scientists developed. He spun out a company, Adagio, to build a universal antibody, one that could snuff out any potential mutation.
Unlock this article along with other benefits by subscribing to one of our paid plans.
Since our start in 2016, Endpoints has grown fast while executing our mission to cover biopharma’s most critical developments for industry pros worldwide. As readership has grown, our advertising business has too. Endpoints advertising partners support the mission and engage their desired audiences through announcements on our email and web platforms, brand recognition in our event coverage and sponsorships of Endpoints daily and weekly reports.
Stéphane Bancel, Moderna CEO
Even as public health officials remain guarded about their comments on the likelihood Omicron will escape the reach of the currently approved Covid-19 vaccines, there’s growing scientific consensus that we’re facing a variant that threatens to overwhelm the vaccine barricades that have been erected.
Stéphane Bancel, the CEO of Moderna, one of the leading mRNA players whose quick vault into the markets with a highly effective vaccine created an instant multibillion-dollar market, added his voice to the rising chorus early Tuesday. According to Bancel, there will be a significant drop in efficacy when the average immune system is confronted by Omicron. The only question now is: How much?
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it’s free.
Barely a month after disappointing data shattered hopes for a major label expansion for the GI tumor drug Qinlock, Deciphera is making a major pivot — scrapping development plans for that drug and discarding another while it hunkers down and focuses on two remaining drugs in the pipeline.
As a result, 140 of its staffers will be laid off.
The restructuring, which claims the equivalent of 35% of its total workforce, will take place across all departments including commercial, R&D as well as general and administrative support functions, Deciphera said, as it looks to streamline Qinlock-related commercial operations in the US while concentrating only on a ‘select number of key European markets.’
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it’s free.
The FDA’s Oncologic Drugs Advisory Committee has decided to cancel a planned meeting on Thursday to discuss two cancer drugs that previously won accelerated approvals but failed to confirm clinical benefit in required follow-up trials or have taken a long time to finish those trials.
The FDA said in a statement that the meeting ‘is no longer needed’ but did not offer further detail on why exactly it was canceled, telling Endpoints News to contact the companies. Attempts to contact both Secura Bio and Acrotech went unreturned. The companies may have decided to pull these treatments from the market, or they’ve come to new agreements with the agency on their confirmatory trials.
Sciwind Biosciences announced last night that it signed an expansive license agreement with Sanofi to develop and commercialize Sanofi’s long-lasting glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. According to Sciwind, the lead candidate is currently under preclinical development.
The deal covers all applicable indications for the molecule. Sciwind plans to develop the lead GIP receptor agonist as part of combination with XWoo3, its GLP-1 peptide candidate which is currently being evaluated in Phase II studies to potentially treat diabetes, obesity and NASH.
https://endpts.com/astrazeneca-turns-down-the-tv-volume-to-drive-up-attention-with-fasenra-asthma-campaign/
